Here are the top 10 takeaways from the late-breaking studies on cardiovascular technologies presented at the 2021 American College of Cardiology (ACC...
Cath Lab
The catheterization lab channel includes content related to interventional technologies for coronary and peripheral artery disease (PAD). Other cath lab transcatheter device technologies covered on this page included percutaneous treatment for stroke, venous interventions, heart valves, hypertension, heart failure and percutenous coronary interventions (PCI).
-
-
June 7, 2021 — A couple years ago a study showed a mortality safety signal in patients who underwent peripheral artery disease (PAD) revascularization with paclitaxel drug-coated devices.
-
June 7, 2021 — Edwards Lifesciences recently announced that clinical results from the company's transcatheter mitral and tricuspid programs, presented as part of the late-breaking clinical trials...
-
June 7, 2021 – Cardiologists at Henry Ford Hospital are first in the U.S.
Blog | Structural Heart | June 08, 2021
It is brutal and very expensive to bring a new transcatheter valve to market. Boston Scientific invested vast amounts...
Some of the top technology news from ACC 2021. Top left, the LAAOS III trial showed benefit when surgeons seal off the LAA during other open heart procedures. Bottom left, the ReCor Paradise renal denervation system helped lower blood pressure in patients who did not respond to medication. Top right, for patients with both heart failure and AFib it makes no difference if therapy is focused on controlling the heart rhythm or heart rate. Bottom right, the FLOWER-MI trial found no benefit to FFR-guided PCI in STEMI with multi-vessel disease.
Feature | ACC | June 08, 2021 | By Dave Fornell, Editor
Here are the top 10 takeaways from the late-breaking studies on cardiovascular technologies presented at the 2021...
Two years ago a study raised concerns that paclitaxel-coated devices may cause increased mortality in peripheral artery disease patients. However, numerous studies now show there is no risk of increased mortality. The most recent study is the SAFE-PAD study presented at ACC.21.
News | Peripheral Artery Disease (PAD) | June 07, 2021
June 7, 2021 — A couple years ago a study showed a mortality safety signal in patients who underwent peripheral artery...
Sponsored Content
Case Study | Cardiovascular Information Systems (CVIS) | April 01, 2021
Washington Health System (WHS) provides healthcare services at more than 40 offsite locations across three counties in...
The 30-day outcomes from the TRISCEND study of the transfemoral Evoque tricuspid valve replacement system demonstrated technical feasibility and an acceptable safety profile, along with improvements in tricuspid regurgitation (TR) and symptoms in patients with clinically significant TR.
News | Structural Heart | June 07, 2021
June 7, 2021 — Edwards Lifesciences recently announced that clinical results from the company's transcatheter mitral...
The Aortix intra-aortic axial flow pump offers hemodynamic support to relieve some of the heart’s workload, allowing the heart to recover while more effectively pushing blood flow to the kidneys.
News | Heart Failure | June 07, 2021
June 7, 2021 – Cardiologists at Henry Ford Hospital are first in the U.S. and second in the world to implant a...
Feature | Structural Heart | June 02, 2021 | Dave Fornell, Editor
June 2, 2021 — The startup company HLT is a part of the Bracco Group, which is developing a new transcatheter aortic...
How to best anticoagulate COVID-19 patients of varying degrees of disease severity has become one of the biggest questions in medicine over the past year and there are more than 80 ongoing trials looking to answer this question. This was the top story in May 2020. Watch a VIDEO interview on this topic. Find more coronavirus-cardiology news.
Feature | June 01, 2021
June 1, 2021 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC)...
Videos | Congenital Heart | May 26, 2021
Tom Jones, M.D., director, cardiac catheterization laboratories, Seattle Children’s Hospital, explains some of the new...
The Acurate neo2 TAVR valve design enhancements include a 60% larger outer sealing skirt to conform to challenging anatomies. This has minimized paravalvular leaks and imporved clinical outcomes compared to the previous-generation Acurate neo Aortic Valve System.
Feature | Structural Heart | May 26, 2021
May 26, 2021 — Data presented at hotline and late-breaking trial sessions at the EuroPCR 2021 congress for the updated...
News | Balloon Catheter | May 20, 2021
May 20, 2021 — Boston Scientific Corporation announced it has initiated the AGENT IDE trial for the Agent Drug-Coated...
Videos | Robotic Systems | May 18, 2021
Ehtisham Mahmud, M.D., division chief of cardiovascular medicine, director of interventional cardiology and the cardiac...
Videos | Robotic Systems | May 18, 2021
Ehtisham Mahmud, M.D., division chief of cardiovascular medicine, director of interventional cardiology and the cardiac...
This trial used a therapeutic hypothermia system that used balloon catheters filled with cooled saline, such as the Zoll Thermogard XP temperature management system.
News | Sudden Cardiac Arrest | May 17, 2021
May 17, 2021 — In patients receiving therapeutic hypothermia after suffering out-of-hospital cardiac arrest, those who...
News | Peripheral Artery Disease (PAD) | May 17, 2021
May 17, 2021 — The anticoagulant rivaroxaban (Xarelto), in addition to low-dose aspirin, significantly reduced the...
The FLOWER-MI trial presented at ACC 2021 found no benefit to FFR-guided PCI in STEMI with multi-vessel disease.
News | FFR Technologies | May 17, 2021
May 17, 2021 — In patients who received a coronary stent for an ST-elevation myocardial infarction (STEMI) heart attack...
